Golgi Neurosciences srl and Breye Therapeutics ApS have established a collaboration to develop Golgi’s P2X7 receptor antagonist program for retinal disorders. The companies have now closed the transfer of the P2X7 receptor antagonist program, which seeks to reduce nerve damage and inflammation in retinal disease and advance development of innovative oral small-molecule therapeutics for retinal disorders.

As quicker, more accurate ways to detect dementia becomes ever more urgent, Cumulus Neuroscience Ltd. has teamed up with the Universities of Bath and Bristol in the U.K. to further develop the Fastball electroencephalogram (EEG) test, a diagnostic test for earlier detection of Alzheimer’s dementia. With one in three people born in the U.K. today likely to develop dementia at some point in their lives, early diagnosis and treatment are essential for them to plan for their future.

Recludix Pharma Inc. has entered into a strategic collaboration with Sanofi SA to develop and commercialize first-in-class oral small-molecule STAT6 (signal transducer and activator of transcription 6) inhibitors for patients with immunological and inflammatory diseases. STAT6 is believed to play a key role in multiple dermatological and respiratory diseases.

Saniona AB has established a new research collaboration with Astronautx Ltd. in Alzheimer’s disease. The aim of the collaboration is to identify new treatments for Alzheimer’s disease and other neurodegenerative conditions by modulating a novel, undisclosed ion channel target. The research collaboration will use Saniona’s proprietary platform, Ionbase, for the modulation of ion channels.

Genequantum Healthcare Co. Ltd. and Inxmed Co. Ltd. have signed a collaboration agreement under which Genequantum has granted nonexclusive licensing of its proprietary conjugation technology to Inxmed, supporting the development of the next generation of targeted antibody-drug conjugates (ADCs).

Eleven Therapeutics Ltd. has established a research collaboration with Novo Nordisk A/S for the identification of novel molecules that promote precise delivery of nucleic acid for cardiometabolic diseases by leveraging Eleven’s innovative Deliveri platform.

Cumulus Oncology Ltd. and Leadxpro AG have signed a research collaboration focused on the discovery and development of small molecules targeting an undisclosed and novel cancer-focused G protein-coupled receptor (GPCR).

Raya Therapeutic Inc. has entered into an early-stage R&D collaboration with Argenx SE to evaluate combinations of Raya’s pipeline of targeted small molecules with a potentially complementary product from Argenx.

A new academic and commercial collaboration between The Institute of Cancer Research, the Bellvitge Biomedical Research Institute (Institut d’Investigació Biomèdica de Bellvitge, IDIBELL) and Vivan Therapeutics (My Personal Therapeutics Ltd.) seeks to create cancer drugs less prone to drug resistance, with a particular focus on drugs that could target KRAS.